Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.

In this descriptive hospital-based study, researchers found that telogen effluvium was the most common cause of hair loss among women aged 20 to 40, with most cases occurring over 6 weeks to 6 months without an associated illness.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This study found that CRP levels were elevated in alopecia areata patients, with an inverse linear association between serum vitamin D and CRP levels specifically noted in ophiasis AA.

This review discusses various causes of hair loss, emphasizing the importance of a structured diagnostic approach, and reports no new clinical findings.

This research focuses on alopecia areata, highlighting the psychological impact, especially of its variant alopecia areata incognita, and provides diagnostic and treatment tips, but does not report specific results.

This article proposes a hypothesis for alopecia areata hair loss patterns and provides epidemiological evidence supporting distinct hair loss characteristics between general cases and those with androgenetic alopecia; it presents no new clinical results.

This review outlines various causes and manifestations of hair loss, highlighting that each type has distinct underlying mechanisms and requires specific treatment approaches, without reporting new clinical results.

This article reviews structured management strategies for diagnosing and treating hair and scalp disorders, offering clinical guidelines and emphasizing the importance of psychosomatic care and patient-therapist communication.

This review discusses recent advances in hair follicle research, highlighting therapeutic and cosmetic applications, but reports no new study results.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

The document concludes that alopecia has various forms, each with specific treatments, but no definitive cure for certain types like CCCA has been proven.

This review discusses diagnostic strategies for pediatric hair loss, emphasizing the importance of thorough examinations and dermoscopy for accurate diagnosis, and reports no new research findings.

The paper concludes that the patchiness of alopecia areata is likely due to when the immune attack happens in the hair growth cycle.

This study observed a significant reduction in the number of hair follicles with a high proportion in catagen or telogen phase, along with visible vertical columns of connective tissue in the histopathologic examination.

This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.

This review discusses various nail changes in alopecia areata and suggests that they may be more prevalent than previously recognized, impacting quality of life and potentially indicating disease progression.

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.

This review discusses emerging evidence on azathioprine's efficacy and safety for severe alopecia areata, reporting sustained response in many patients but emphasizing the need for controlled trials.

This review discusses the potential of superficial cryotherapy as an effective and safe treatment for alopecia areata in eyebrows, with a proposed mechanism involving improved follicular nutrition, but reports no new clinical results.

In this observational study, researchers found that socioeconomic factors and stress significantly influence alopecia areata in patients in the Indian subcontinent.

This review examines the clinical presentation and management strategies for alopecia areata, focusing on pediatric patients, and highlights the need for addressing its psychological impacts; it reports no new clinical findings.

This study observed that while dermoscopic features in alopecia areata for dark-skinned individuals align with existing literature, yellow dots appear more frequently and could help in grading disease severity.

This study found that videodermoscopy enhances diagnostic accuracy for scalp and hair disorders beyond simple clinical inspection and reveals novel disease features that could improve clinical understanding.

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.

This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.